Systemic administration of imiquimod as an adjuvant improves immunogenicity of a tumor-lysate vaccine inducing the rejection of a highly aggressive T-cell lymphoma
T-cell lymphomas include diverse malignancies. They are rare, some have low survival rates and they lack curative therapies. The aim of this work was to assess whether employing the TLR7 agonist imiquimod and the T-cell costimulatory molecule CD40 or the combination of both as adjuvants of a cell ly...
| Main Authors: | , , , , , |
|---|---|
| Format: | info:ar-repo/semantics/artículo |
| Language: | Inglés |
| Published: |
Elsevier
2019
|
| Subjects: | |
| Online Access: | https://www.sciencedirect.com/science/article/pii/S1521661618304212 http://hdl.handle.net/20.500.12123/6229 https://doi.org/10.1016/j.clim.2019.04.013 |
Similar Items: Systemic administration of imiquimod as an adjuvant improves immunogenicity of a tumor-lysate vaccine inducing the rejection of a highly aggressive T-cell lymphoma
- Exosomes Isolated from Ascites of T-Cell Lymphoma-Bearing Mice Expressing Surface CD24 and HSP-90 Induce a Tumor-Specific Immune Response
- Cyclophosphamide enhances the release of tumor exosomes that elicit a specific immune response in vivo in a murine T-cell lymphoma
- MANα1-2MAN decorated liposomes enhance the immunogenicity induced by a DNA vaccine against BoHV-1
- Immunogenicity of hypothetical highly conserved proteins as novel antigens in Anaplasma marginale
- Deletion of A44L, A46R and C12L vaccinia virus genes from the MVA genome improved the vector immunogenicity by modifying the innate immune response generating enhanced and optimized specific T-Cell responses
- A plasmid encoding the extracellular domain of CD40 ligand and MontanideTM GEL01 as adjuvants enhance the immunogenicity and the protection induced by a DNA vaccine against BoHV-1